Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity.
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus.
Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment.
Exploring barriers, needs, and facilitators for clinical and translational research in Oklahoma: A sequential mixed-methods study.
